Abstract
The immune system of healthy individuals is capable of regulating autoimmunity through multiple mechanisms. In Type 1 Diabetes (T1D) we recently discovered natural IgM, although present at normal levels, is unable to perform its normal immunoregulatory function. Treating diabetic mice with IgM from healthy donors led to reversal of disease without immune depletion. To investigate the therapeutic potential of a human preparation of IgM, we administered an IgM-enriched preparation of immunoglobulin called Pentaglobin. Administration of Pentaglobin therapy reversed disease in diabetic NOD mice and boosted CD4 + Foxp3 + Tregs. Importantly, the impact of Pentaglobin on the immune system was limited to inhibiting beta cell destruction but was not immune depleting nor did it inhibit the immunization response to an irrelevant antigen. These findings indicate that inhibition of deleterious autoimmunity in T1D is possible while leaving protective immunity fully intact.
Similar content being viewed by others
Introduction
Type 1 diabetes (T1D) is an autoimmune disease that results from the collaboration of T and B lymphocytes to drive the destruction of beta cells of the islet1,2. Destruction of beta cells leads to the need for continuous insulin therapy that, while life sustaining, comes with the potential for multiple co-morbidities even with tight glucose control3. Curative therapy is sorely needed to curb the risk that treatment with insulin poses to patients with T1D. To this end, immunologic interventions have been attempted clinically to reverse or prevent T1D. While some interventions provide modest retention of C-peptide, none are curative, and each currently appears to require repeated therapy to prevent disease progression, which will result in immune suppression ranging from intermittent to continuous4,5,6,7. With the emergence of the global COVID-19 pandemic, which poses an increased threat to those with T1D, it is clear that the current intervention paradigm in T1D that utilizes therapies that impede or suppress autoimmunity at the expense of normal immunity is a significant risk to the community8.
The homeostatic maintenance of the immune compartment is crucial for normal immune function. Studies have demonstrated that abnormal immune homeostasis, including lymphopenia, encourages the emergence of autoreactive cell subsets that hasten autoimmunity. In T1D there is evidence of abnormal immune homeostasis in both animal models and humans, including altered T cell and B cell development, altered cell subsets, and production of autoantibodies9,10,11. We have previously demonstrated the circulating IgM from healthy donors has the capacity to restore immune homeostasis and reverse T1D without global immune depletion when administered therapeutically12.
To understand the therapeutic potential of human IgM, we investigated the ability of a preparation of IgM-enriched human immunoglobulins (Pentaglobin) to reverse diabetes in NOD mice. This clinically-utilized therapy has been applied as an adjuvant therapy in bacterial sepsis, but its efficacy in autoimmunity remains unknown13,14. We determined that Pentaglobin reverses diabetes in NOD mice and enhances Treg generation, while leaving the protective function of the immune system intact. These data indicate that immune dysfunction in T1D can be treated without immune depletion or suppression and indicate the potential for harnessing endogenous immune regulators to provide autoimmune regulation without immune suppression.
Results
Pentaglobin, an immunoglobulin preparation enriched in human IgM, reverses diabetes in NOD mice
Our previous studies of purified polyclonal IgM to reverse diabetes in NOD mice utilized 2 peritoneal injections of 100ug of IgM12. Based on these studies, we utilized a similar reversal strategy with Pentaglobin doses containing the equivalent of 35ug, 100ug, and 300ugs of IgM, which equaled a dose of 300ug, 875ug, and 2.6mgs of total Pentaglobin (78.5% IgG 10% IgA and 11.5% IgM), respectively. NOD mice were deemed diabetic after two consecutive days of blood glucose readings between 200-300 mg/dl. After the second elevated glucose reading, mice were treated with the indicated dose of Pentaglobin on day 1 and then again 3 days after the initial dose. Mice were considered reversed after 2 consecutive days of readings below 200 mg/dl and were scored diabetic after 2 consecutive days above 200 mg/dl. Utilizing this approach, we demonstrated 40% total reversal in the 300ug and 875ug dosing but only saw ~ 20% total reversal with 2.6 mg dosing. Since the higher dosing strategies showed no improvement over the 300ug dosing, we chose the 300ug (30ug of IgM) dose to further study for diabetes reversal (Fig. 1A). We hypothesized two additional doses would provide improved reversal in these mice (Fig. 1B). This dosing strategy led to initial reversal of ~ 78% of mice enrolled in the study and ~ 33% remained diabetes-free for 90 days after the initial dose (Fig. 1C and D). The overall reversal may favor those mice with a slightly lower starting blood glucose (240mgl/dl for stably reversed at 90 days and ~ 265 mg/dl average for those that did not stably reverse) although these differences were not statistically significant (p = 0.5, t-test). Importantly, we observed no mouse anti-human antibodies (MAHA) in these mice (Supplemental Fig. 1A).
Pentaglobin reversal is linked to expanded thymic B cells and Tregs
Diabetes reversal by healthy mouse IgM in NOD mice was associated with expansion of thymic B cells and Tregs12. To determine whether Pentaglobin modulated the immune system in the same way as healthy mouse IgM, we treated prediabetic NOD mice with two doses of 300ug of Pentaglobin (Fig. 2A). Thymic cell counts trended toward an expansion of total thymocytes in NOD mice treated with Pentaglobin but did not reach statistical significance (Fig. 2B). Flow analysis revealed increases in total B cells in the thymus of NOD mice compared to controls (Fig. 2C right panels and quantified in D). These thymic B cells were essential for expansion of thymic Tregs in our previous studies of treatment with natural IgM. Our studies with Pentaglobin indicate that thymic B cell expansion is also accompanied by increase in total Tregs as observed in the thymus of NOD mice treated with Pentaglobin (Fig. 2E right panels and quantified in F).
Pentaglobin expands peripheral Tregs but does not induce suppression of normal immunity
We observed that thymic expansion of Tregs was maintained in the splenic compartment of NOD mice treated with Pentaglobin (Fig. 3A). This observation links to the mechanism observed in NOD mice treated with mouse polyclonal IgM as Tregs were essential for stable disease reversal in those prior studies12. As with treated, diabetic mice, prediabetic NOD and B6 mice generated no MAHA response after Pentaglobin (Fig. 3B) As our studies indicate, repeated dosing of Pentaglobin even beyond 4 days may be important for stable reversal of T1D in a clinical setting as is the case with other current investigational interventions for T1D. Readministration of these other therapies may be limited due to their immune-depleting or suppressing nature, which may leave patients susceptible to infection, cancer, or other unknown risks that may be exacerbated as treatment courses are extended. While cell counts and flow cytometry demonstrated that Pentaglobin was not immune depleting, we further investigated whether it inhibits the proliferative capacity of protective T cells. Proliferation was similar in both CD4 and CD8 T cells in NOD mice treated with Pentaglobin or left untreated (control) (Fig. 3C–F). To assess the ability of Pentaglobin-treated NOD mice to respond to an immune challenge, mice were immunized with NP33/KLH/IFA. To assess how Pentaglobin impacts this immune response to NP, we treated NOD mice on day -1 before immunization with 300ug of Pentaglobin and again on day 7. Both the low-affinity (NP25) and the high-affinity (NP8) anti-NP IgG response were analyzed by ELISA on day 17. We detected no difference in anti-NP titers in NOD mice treated with Pentaglobin (Fig. 3H and I). Flow cytometry analysis of spleens from immunized mice demonstrated similar levels of Germinal Center B cells and T-follicular helper cells between treated and untreated mice (Fig. 3J and K).
Discussion
This study indicates that the immune dysfunction in autoimmune T1D in NOD mice can be treated without immune suppression. This non-suppressive immune therapy was accomplished with a clinically-used, human immunoglobulin preparation that contains increased amounts of IgM (12%), Pentaglobin. This study highlights the need and opportunity to advance non-suppressive strategies that can reset immune homeostasis while maintaining protection from the threat of infectious disease in persons with T1D.
Intravenous immunoglobulin (IVIg) therapy has shown effectiveness in many immune conditions but failed to reverse clinical disease in T1D15. These preparations contain mostly pooled IgGs from human donors and very little IgM. While IgG is a widely utilized therapy, IgM is the most abundant, non-induced antibody found in circulation in humans and mice16. It is produced continuously by marginal zone B cells of the spleen and B1 B cells, located in the peritoneal cavity and bone marrow of mice17. IgM is the first line of defense against invading pathogens. It can regulate immune homeostasis in B and T cells, and its absence leads to perturbed immune cell development similar to that observed in NOD mice18,19. Previous studies indicate that purified IgM isolated from both healthy human and murine donors could prevent as well as reverse diabetes in NOD mice as well as modulate B cell homeostasis and Treg expansion12,20.
Pentaglobin is currently utilized as an adjuvant therapy in patients with sepsis. It has been observed in some studies to reduce mortality rates in patients with any level of sepsis severity14. This finding indicates that Pentaglobin can inhibit deleterious immunity, responsible for the morbidity associated with severe sepsis, while allowing ongoing clearance of infection. Our data support this model, as we demonstrated reversal of autoimmunity and enhancement of Tregs but did not observe immune suppression in T cell or B cell responses. This important property makes Pentaglobin an ideal candidate for T1D therapy where children are the primary recipients and where current therapies are largely immune depleting and suppressing making their continual delivery unfavorable.
Pentaglobin induced robust diabetes reversal in newly diabetic NOD mice. This reversal was linked to changes in thymic B cell and Treg populations. These changes were also observed with treatment of purified murine donor IgMs from healthy mice in our previous study12. We did not observe peripheral alterations of B cell subsets in NOD mice treated with Pentaglobin as we did with murine IgM, which may account for some differences in the observed effect on diabetes in the animal model (Supplemental 2). Nevertheless, Pentaglobin induced a modest expansion in peripheral Tregs. The reasons for these differences in immune modulation may relate to species-specific interactions. These interactions and their impact on immune function and disease demand further investigation in a clinical setting. Applying Pentaglobin therapy to humans with T1D will require monitoring increases in Tregs, especially those newly emigrated from the thymus.
The immune regulation of IgM has been linked to antigen specificity, structural changes, and glycosylation patterns18,19,21,22,23,24,25. It is possible that the human IgM bound with less affinity to immune cell subsets, due to epitope differences in cell surface molecules. While we provided the same total amount of IgM as previous studies, the amount of effective, therapeutic IgM may have differed due to the different isolation techniques. Additionally, the amount of IgG delivered concomitantly with IgM may have counteracted or masked immune changes induced by IgM alone. The higher dosage, while containing more IgM, was less effective at diabetes reversal, suggesting interactions with other components of Pentaglobin.
Maintaining normal immune function should be an important consideration when selecting an immune therapeutic for T1D or any autoimmune disease, but the degree and duration of immune suppression is not commonly quantified in either pre-clinical or clinical studies to date. This investigation highlights the potential for immune therapeutics that do not deplete or suppress the immune system in autoimmune disease. Overall, the therapeutic application for IgM-enriched therapeutics in T1D is an untapped avenue that holds great promise outside of its current clinical applications.
Materials and methods
Animals
C57BL/6 J (B6) and NOD/ShiLtJ (NOD) mice were purchased from The Jackson Laboratory (Bar Harbor, ME), Mice were housed in a specific-pathogen–free facility at Vanderbilt University. Female mice were used in this study as the penetrance of diabetes is much higher. No male mice were used in this study. Animal experiments were reviewed and approved by the Vanderbilt IACUC in keeping with ethical principles. The study is designed, performed, and reported in keeping with ARRIVE guidelines.
Pentaglobin treatment and dosage
Pentaglobin was provided by Biotest AG (Dreieich, Germany); Biotest AG did not have any other contributions to the study design or data interpretation. For diabetes reversal, NOD mice were treated by i.p. injection with (300 μg) of Pentaglobin on day 1, 4, 7, and 10 after diabetes onset. For cellular analysis, NOD and B6 mice were treated by i.p. injection with an initial dose of 300 μg Pentaglobin on day 1 followed by 300-μg doses on days 4 and sacrificed on day 10.
Flow cytometry and antibodies
Spleen and thymus were rendered to single-cell suspensions by crushing through a 70-μm filter. Splenocytes or thymocytes were stained with fluorophore-conjugated antibodies purchased from either BD Biosciences (San Jose, CA), eBioscience (San Diego, CA).
Mouse-anti human antibody ELISA
25uls of murine serum was collected via submandibular bleed from each mouse before and after Pentaglobin treatment. The mouse anti-human antibody (MAHA) ELISA (Eagle Biosciences) was carried out according to manufacturer’s directions. It was read at 450 nm absorbance on a plate reader. Concentration of anti-human IgG was determined via standard curve, and validated via internal controls of know concentration provided by the manufacturer.
Statistics
Statistical analysis was performed with Prism 5 software (GraphPad, La Jolla, CA) using the Mann–Whitney U test. One- or two-way ANOVA followed by Bonferroni posttest was used to compare multiple groups. Statistical comparisons with P ≤ 0.05 were deemed significant.
Study approval
The institutional animal care and use committee at Vanderbilt University approved all procedures carried out during this study.
References
Moore, D. J., Noorchashm, H., Lin, T. H., Greeley, S. A. & Naji, A. NOD B-cells are insufficient to incite T-cell-mediated anti-islet autoimmunity. Diabetes 54, 2019–2025 (2005).
Greeley, S. A. et al. Impaired activation of islet-reactive CD4 T cells in pancreatic lymph nodes of B cell-deficient nonobese diabetic mice. J. Immunol. 167, 4351–4357 (2001).
Brown, A., Reynolds, L. R. & Bruemmer, D. Intensive glycemic control and cardiovascular disease: an update. Nat. Rev. Cardiol. 7, 369–375 (2010).
Chamberlain, N. et al. Rituximab does not reset defective early B cell tolerance checkpoints. J. Clin. Invest. 126, 1–6. https://doi.org/10.1172/JCI83840DS1 (2016).
Pescovitz, M. D. et al. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care 37, 453–459. https://doi.org/10.2337/dc13-0626 (2014).
Herold, K. C. et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692–1698. https://doi.org/10.1056/NEJMoa012864 (2002).
Rigby, M. R. et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J. Clin. Investig. 125, 1–12. https://doi.org/10.1172/JCI81722DS1 (2015).
Gregory, J. M. et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes. Diabetes Care 44, 526–532. https://doi.org/10.2337/dc20-2260 (2021).
Zekavat, G. et al. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in non-obese diabetic (NOD) mice. J. Immunol. https://doi.org/10.4049/jimmunol.181.11.8133 (2008).
Hulbert, C., Riseili, B., Rojas, M. & Thomas, J. W. Cutting edge: B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J. Immunol. 167, 5535–5538. https://doi.org/10.4049/jimmunol.167.10.5535 (2001).
Insel, R. A. et al. Staging presymptomatic type 1 diabetes: A scientific statement of jdrf, the endocrine society, and the American diabetes association. Diabetes Care 38, 1964–1974. https://doi.org/10.2337/dc15-1419 (2015).
Wilson, C. S. et al. Healthy donor polyclonal IgM’s diminish B lymphocyte autoreactivity, enhance treg generation, and reverse T1D in NOD mice. Diabetes https://doi.org/10.2337/db18-0456 (2018).
Jackson, S. K. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur. J. Clin. Invest. 23, 540–545. https://doi.org/10.1111/j.1365-2362.1993.tb00963.x (1993).
Tuğrul, S. et al. The effect of pentaglobin therapy on prognosis in patients with severe sepsis. Ulus. Travma Derg. 7, 219–223 (2001).
Colagiuri, S. et al. Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. Clin. Exp. Rheumatol. 14(Suppl 1), S93–S97 (1996).
Gonzalez-Quintela, A. et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin. Exp. Immunol. 151, 42–50. https://doi.org/10.1111/j.1365-2249.2007.03545.x (2008).
Choi, Y. S., Dieter, J. A., Rothaeusler, K., Luo, Z. & Baumgarth, N. B-1 cells in the bone marrow are a significant source of natural IgM. Eur. J. Immunol. 42, 120–129. https://doi.org/10.1002/eji.201141890 (2012).
Nguyen, T. T. T., Elsner, R. & Baumgarth, N. Natural IgM prevents autoimmunity by enforcing B cell central tolerance induction. J. Immunol. 194, 1489–1502. https://doi.org/10.4049/jimmunol.1401880 (2015).
Ouchida, R. et al. Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival, and humoral immune responses. Proc. Natl. Acad. Sci. 109, E2699–E2706. https://doi.org/10.1073/pnas.1210706109 (2012).
Chhabra, P., Schlegel, K., Okusa, M. D., Lobo, P. I. & Brayman, K. L. Naturally occurring immunoglobulin M (nIgM) autoantibodies prevent autoimmune diabetes and mitigate inflammation after transplantation. Ann. Surg. 256, 634–641. https://doi.org/10.1097/SLA.0b013e31826b4ba9 (2012).
Nguyen, T. T. T. et al. The IgM receptor FcμR limits tonic BCR signaling by regulating expression of the IgM BCR. Nat. Immunol. 18, 321–333. https://doi.org/10.1038/ni.3677 (2017).
Colucci, M. et al. Sialylation of N-linked glycans influences the immunomodulatory effects of IgM on T cells. J. Immunol. 194, 151–157. https://doi.org/10.4049/jimmunol.1402025 (2015).
Vas, J., Grönwall, C., Marshak-Rothstein, A. & Silverman, G. J. Natural antibody to apoptotic cell membranes inhibits the proinflammatory properties of lupus autoantibody immune complexes. Arthritis Rheum. 64, 3388–3398. https://doi.org/10.1002/art.34537 (2012).
Lobo, P. I. et al. Natural IgM anti-leukocyte autoantibodies attenuate excess inflammation mediated by innate and adaptive immune mechanisms involving Th-17. J. Immunol. 188, 1675–1685. https://doi.org/10.4049/jimmunol.1101762 (2012).
Notley, C., Baker, N. & Ehrenstein, M. R. Secreted IgM enhances B cell receptor signaling and promotes splenic but impairs peritoneal B cell survival. J. Immunol. 184, 3386–3393. https://doi.org/10.4049/jimmunol.0902640 (2010).
Funding
Funding was provided by National Institute of Diabetes and Digestive and Kidney Diseases grant number 3T32DK007061-48S1 and 1R56DK128337-01 and by National Institute of Allergy and Infectious Diseases (NIAID) 1R21AI119224-01.
Author information
Authors and Affiliations
Contributions
C.S.W. and D.J.M. designed the experiments and wrote the manuscript. C.S.W., E.H., and A.F. performed experiments and analyzed data. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wilson, C.S., Hoopes, E.M., Falk, A.C. et al. A human IgM enriched immunoglobulin preparation, Pentaglobin, reverses autoimmune diabetes without immune suppression in NOD mice. Sci Rep 12, 11731 (2022). https://doi.org/10.1038/s41598-022-15676-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-022-15676-8
- Springer Nature Limited